(NASDAQ: DXCM) Dexcom's forecast annual revenue growth rate of 8.61% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 6.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.15%.
Dexcom's revenue in 2026 is $5,104,400,000.On average, 32 Wall Street analysts forecast DXCM's revenue for 2026 to be $1,988,947,267,026, with the lowest DXCM revenue forecast at $1,902,795,604,044, and the highest DXCM revenue forecast at $2,055,332,531,142. On average, 32 Wall Street analysts forecast DXCM's revenue for 2027 to be $2,195,562,077,814, with the lowest DXCM revenue forecast at $2,079,201,390,150, and the highest DXCM revenue forecast at $2,288,426,857,392.
In 2028, DXCM is forecast to generate $2,447,676,901,086 in revenue, with the lowest revenue forecast at $2,260,455,538,242 and the highest revenue forecast at $2,772,890,105,070.